Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Raymond James to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $46.00 price target on the stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]